These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32150255)

  • 1. Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain.
    Henningfield JE; Gudin J; Rauck R; Gimbel J; Tagliaferri M; Doberstein SK; Di Fonzo C; Lu L; Katz N; Siddhanti S; Schnoll S
    Pain Med; 2020 Aug; 21(8):1553-1561. PubMed ID: 32150255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Drug Event Reporting System).
    Lanier RK; Henningfield JE; Gudin J; Rauck R; Elder H; Erpelding N; Treister R; Gimbel J; Tagliaferri M; Doberstein SK; Di Fonzo CJ; Lu L; Siddhanti S; Katz NP
    Curr Med Res Opin; 2019 Sep; 35(9):1513-1522. PubMed ID: 30932719
    [No Abstract]   [Full Text] [Related]  

  • 3. SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain.
    Markman J; Gudin J; Rauck R; Argoff C; Rowbotham M; Agaiby E; Gimbel J; Katz N; Doberstein SK; Tagliaferri M; Lu L; Siddhanti S; Hale M
    Pain; 2019 Jun; 160(6):1374-1382. PubMed ID: 30747908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS).
    Gudin J; Rauck R; Argoff C; Agaiby E; Gimbel J; Katz N; Doberstein SK; Tagliaferri M; Tagliaferri M; Potts J; Wild J; Lu L; Siddhanti S; Hale M; Markman J
    Pain Med; 2020 Nov; 21(7):1347-1356. PubMed ID: 31361019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
    Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
    Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
    Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
    Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain.
    Katz N; Kopecky EA; O'Connor M; Brown RH; Fleming AB
    Pain; 2015 Dec; 156(12):2458-2467. PubMed ID: 26262828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
    Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
    Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of negative affect and outcome of an opioid therapy trial among low back pain patients.
    Jamison RN; Edwards RR; Liu X; Ross EL; Michna E; Warnick M; Wasan AD
    Pain Pract; 2013 Mar; 13(3):173-81. PubMed ID: 22681407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.
    Palangio M; Morris E; Doyle RT; Dornseif BE; Valente TJ
    Clin Ther; 2002 Jan; 24(1):87-99. PubMed ID: 11833838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.
    Gimbel J; Spierings ELH; Katz N; Xiang Q; Tzanis E; Finn A
    Pain; 2016 Nov; 157(11):2517-2526. PubMed ID: 27434505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.